Skip to content

Camber Capital Management LP 13F Holdings · last filed Q2 2025

Camber Capital Management LP reported 23 securities worth $1.07B in its SEC 13F filing for Q2 2025 (period ended 2025-06-30). Top holdings: SPY (29.00%), ZBH (8.56%), BAX (8.10%). Among its top 25 positions this quarter: 4 new, 1 added, 17 trimmed.

RankTickerCompanyValue% PortfolioSharesAction
1SPYSPDR S&P 500 ETF TR$308.9M29.00%500,000Trimmed
2ZBHZIMMER BIOMET HOLDINGS INC$91.2M8.56%1.0MTrimmed
3BAXBAXTER INTL INC$86.3M8.10%2.9MTrimmed
4HUMHUMANA INC$73.3M6.89%300,000Trimmed
5CVSCVS HEALTH CORP$72.4M6.80%1.1MTrimmed
6GMEDGLOBUS MED INC$47.2M4.43%800,000Trimmed
7ICLRICON PLC$43.6M4.10%300,000New
8ASNDASCENDIS PHARMA A/S$43.1M4.05%250,000Trimmed
9MRKMERCK & CO INC$39.6M3.72%500,000New
10GSKGSK PLC$38.4M3.60%1.0MHold
11PFEPFIZER INC$36.4M3.41%1.5MTrimmed
12BMRNBIOMARIN PHARMACEUTICAL INC$33.0M3.10%600,000Added
13UNHUNITEDHEALTH GROUP INC$31.2M2.93%100,000New
14VTRSVIATRIS INC$24.6M2.31%2.8MTrimmed
15BKDBROOKDALE SR LIVING INC$15.0M1.40%2.1MTrimmed
16ZIMVZIMVIE INC$15.0M1.40%1.6MTrimmed
17APLSAPELLIS PHARMACEUTICALS INC$14.7M1.38%850,000New
18MYGNMYRIAD GENETICS INC$10.6M1.00%2.0MTrimmed
19EVHEVOLENT HEALTH INC$9.6M0.90%850,000Trimmed
20CONCONCENTRA GROUP HOLDINGS PAR$8.2M0.77%400,000Trimmed
21INGNINOGEN INC$6.9M0.64%975,000Hold
22DNLIDENALI THERAPEUTICS INC$5.6M0.53%400,000Trimmed
23TBPHTHERAVANCE BIOPHARMA INC$5.0M0.47%450,000Trimmed
24ANABANAPTYSBIO INC$2.8M0.26%125,000Trimmed
25OSURORASURE TECHNOLOGIES INC$2.7M0.25%900,000Hold

Source: SEC Form 13F filings · as of 2025-06-30

Every position in this 13F-HR, with its change from the prior quarter.

13F holdings, latest quarter

SourceSEC EDGAR13F-HR